A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2016
At a glance
- Drugs ABT 436 (Primary)
- Indications Anxiety disorders; Depression
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Abbott Laboratories
- 13 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jan 2010 New trial record